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Abstract: Although malignant cells can be recognized and controlled by the immune system, in patients
with clinically apparent cancer immunosurveillance has failed. To better understand local immunoreg-
ulatory processes that impact on cancer progression, we correlated intratumoral immunological profiles
with the survival of patients affected by primary clear cell renal cell carcinoma (ccRCC). A retrospective
analysis of 54 primary ccRCC samples for 31 different immune response-related transcripts, revealed a
negative correlation of CD68 (a marker of tumor-associated macrophages, TAMs) and FOXP3 (a marker
of regulatory T cells, Tregs) with survival. The subsequent analysis of 12 TAM-related transcripts re-
vealed an association between the genes coding for CD163, interferon regulatory factor 4 (IRF4) and
fibronectin 1 (FN1), all of which have been linked to the M2 TAM phenotype, with reduced survival
and increased tumor stage, whereas the opposite was the case for the M1-associated gene coding for
inducible nitric oxide synthetase (iNOS). The M2 signature of (CD68(+)) TAMs was found to corre-
late with CD163 expression, as determined in prospectively collected fresh ccRCC tissue samples. Upon
co-culture with autologous tumor cells, CD11b(+) cells isolated from paired blood samples expressed
CD163 and other M2-associated proteins, suggesting that the malignant cells promote the accumulation
of M2 TAMs. Furthermore, the tumor-associated milieu as well as isolated TAMs induced the skewing
of autologous, blood-derived CD4(+) T cells toward a more immunosuppressive phenotype, as shown by
decreased production of effector cytokines, increased production of interleukin-10 (IL-10) and enhanced
expression of the co-inhibitory molecules programmed death 1 (PD-1) and T-cell immunoglobulin mucin
3 (TIM-3). Taken together, our data suggest that ccRCC progressively attracts macrophages and induces
their skewing into M2 TAMs, in turn subverting tumor-infiltrating T cells such that immunoregulatory
functions are increased at the expense of effector functions.
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Introduction
It is well established that the immune system recognizes and can 
destroy tumor cells, and a significant association between immune 
infiltration and disease outcome has been described in many dif-
ferent cancers.1 However, the interactions between immune cells 
and tumor cells are complex and we are only beginning to under-
stand them. According to current models, malignant cells and 
immune cells mutually influence each other, ultimately result-
ing in the escape of the former from immunosurveillance, such 
as in patients with clinically manifest cancer.2 Besides tumor 
cell-intrinsic escape mechanisms, including the downregula-
tion of MHC Class I and II molecules and/or tumor-associated 
antigens (TAAs), neoplastic cells can create a microenvironment 
although malignant cells can be recognized and controlled by the immune system, in patients with clinically apparent 
cancer immunosurveillance has failed. To better understand local immunoregulatory processes that impact on cancer 
progression, we correlated intratumoral immunological profiles with the survival of patients affected by primary clear 
cell renal cell carcinoma (ccRcc). a retrospective analysis of 54 primary ccRcc samples for 31 different immune response-
related transcripts, revealed a negative correlation of cD68 (a marker of tumor-associated macrophages, TaMs) and FOXp3 
(a marker of regulatory T cells, Tregs) with survival. The subsequent analysis of 12 TaM-related transcripts revealed an 
association between the genes coding for cD163, interferon regulatory factor 4 (IRF4) and fibronectin 1 (FN1), all of which 
have been linked to the M2 TaM phenotype, with reduced survival and increased tumor stage, whereas the opposite was 
the case for the M1-associated gene coding for inducible nitric oxide synthetase (iNOs). The M2 signature of (cD68+) TaMs 
was found to correlate with cD163 expression, as determined in prospectively collected fresh ccRcc tissue samples. Upon 
co-culture with autologous tumor cells, cD11b+ cells isolated from paired blood samples expressed cD163 and other 
M2-associated proteins, suggesting that the malignant cells promote the accumulation of M2 TaMs. Furthermore, the 
tumor-associated milieu as well as isolated TaMs induced the skewing of autologous, blood-derived cD4+ T cells toward 
a more immunosuppressive phenotype, as shown by decreased production of effector cytokines, increased production 
of interleukin-10 (IL-10) and enhanced expression of the co-inhibitory molecules programmed death 1 (pD-1) and T-cell 
immunoglobulin mucin 3 (TIM-3). Taken together, our data suggest that ccRcc progressively attracts macrophages and 
induces their skewing into M2 TaMs, in turn subverting tumor-infiltrating T cells such that immunoregulatory functions 
are increased at the expense of effector functions.
Tumor-associated macrophages subvert  
T-cell function and correlate with reduced survival 
in clear cell renal cell carcinoma
stefanie Regine Dannenmann,1 Julia Thielicke,1 Martina stöckli,1 claudia Matter,1 Lotta von Boehmer,1 Virginia cecconi,1 
Thomas hermanns,2 Lukas hefermehl,2 peter schraml,3 holger Moch,3 alexander Knuth1 and Maries van den Broek1,*
1Department of Oncology; University hospital Zurich; Zurich, switzerland; 2Department of Urology; University hospital Zurich; Zurich, switzerland;  
3Department of pathology; University hospital Zurich; Zurich, switzerland
Keywords: clear cell renal cell carcinoma, immunoregulation, T-cell response, tumor-associated macrophages, tumor immunology
Abbreviations: ccRCC, clear cell renal cell carcinoma; ICS, intracellular cytokine stain; qRT-PCR, quantitative reverse 
transcription real-time PCR; TAM, tumor-associated macrophage; TIL, tumor-infiltrating leukocyte
that interferes with immune effector mechanisms. Thus, cancer 
cells can secrete immunosuppressive cytokines such as interleu-
kin (IL)-10 and transforming growth factor β (TGFβ)3,4 and 
promote the recruitment of immunoregulatory cell types such 
as regulatory T cells (Tregs), specific subsets of tumor-associ-
ated macrophages (TAMs) and myeloid-derived suppressor cells 
(MDSCs).5–7 CD68 is expressed by macrophages and preclinical 
data indicate that TAMs most often exert tumor-promoting func-
tions by stimulating angiogenesis, tumor-cell proliferation and 
metastasis, as well as by contributing to the subversion of adaptive 
immune responses.8 TAMs show a remarkable degree of plasticity 
and it has recently been shown that the conversion of pro-inflam-
matory M1 macrophages to so-called “alternatively-activated” 
M2 macrophages9 and/or the preferential accumulation10 of the 
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the 31 transcripts with survival, using Cox regression analysis 
(Fig. 1A; Fig. S1A). We excluded the data for lymphotoxin α 
(LTα), arginase 1, B and T lymphocyte associated (BTLA), IL-2 
and IL-17 from the analysis because of very low or undetectable 
expression. Univariate Cox regression analysis revealed a signifi-
cant correlation of elevated FOXP3 (a marker of Tregs) and CD68 
(a marker of macrophages) mRNA levels with reduced survival, 
whereas the abundance of CD3 transcripts (identifying T cells 
as a whole) did not correlate with patient survival (Fig. 1A). We 
correlated the abundance of CD68 transcripts with that of CD3, 
CD4 and CD8 transcripts, finding no correlation between CD68 
and CD3 (correlation coefficient −0.082, two-tailed p = 0.556) 
or CD68 and CD8 (correlation coefficient −0.031, two-tailed 
p = 0.882), but a significant correlation between CD68 and CD4 
(correlation coefficient 0.391, two-tailed p = 0.003). The latter 
correlation is positive, presumably reflecting the co-existence of 
macrophages and regulatory T cells. Furthermore, high expres-
sion levels of perforin and tumor necrosis factor α (TNFα) corre-
lated with increased survival, while high expression levels of the 
lymphotoxin β receptor (LTβR) were associated with reduced 
survival (Fig. S1A). Since these associations turned out to be sig-
nificant by means of only one out of two statistical tests employed, 
these genes were not considered to significantly correlate with 
survival. No signal was observed for cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) and IL-10 in a few samples, and 
an estimated Ct value (40) was set for these samples (Fig. S1A). 
When such “no-signal” samples were excluded from the analysis, 
high expression values of CTLA-4 and IL-10 significantly corre-
lated with reduced survival (Fig. S1B). Also other genes (marked 
with an asterisk in Fig. S1) failed to provide a signal in a few 
samples. However, statistical analyses did not significantly vary 
when “no-signal” samples were excluded (data not shown).
While the correlation of FOXP3 expression levels and survival 
just reached the level of statistical significance using univariate 
Cox regression analysis, the correlation between CD68 mRNA 
levels and reduced survival was independent of tumor size and 
patient age, as assessed by multivariate Cox regression analysis 
(Fig. 1). To validate qRT-PCR results, we quantified CD68 by 
immunohistochemistry on seven ccRCC tumor samples and we 
invariably found a clear correlation between the mRNA and pro-
tein levels of CD68 (Fig. S2).
The expression of M2-associated transcripts correlates with 
reduced survival in ccRCC. To further investigate the phenotype 
and impact of TAMs on ccRCC patient survival, we analyzed the 
same samples (Table S2) for the expression levels of additional 
12 TAM-associated genes (Fig 1B; Table S1B; Fig. S1C). We 
found a significant correlation between decreased survival and 
low levels of iNOS or high levels of CD163 transcripts (Fig. 1B). 
Multivariate Cox regression analysis revealed that both correla-
tions are independent of tumor stage and patient age (Fig. 1). 
Along similar lines, a high expression of the M2-associated genes 
FN1 and IRF4 tended to correlate with reduced survival (Fig. 1B). 
Furthermore, we observed a positive correlation between the 
abundance of CD163 transcripts and that of mRNAs coding 
for the M2-associated proteins MR, IL-10 and FN1 as well as a 
negative correlation between the expression levels of CD163 and 
latter within neoplastic lesions exert critical tumor-promoting 
effects. M1 macrophages express the transcription factor inter-
feron regulatory factor (IRF)511 and are thought to bear antitu-
mor activities because of an IL-12highIL-10low phenotype5 coupled 
to elevated expression levels of the inducible nitric oxide (NO) 
synthetase (iNOS),12 resulting in increased production of NO. 
M2 macrophages express the transcription factor IRF413 and are 
characterized by an IL12lowIL10high phenotype,5 the expression of 
the scavenger receptor CD163,14 the mannose receptor (MR)15 
and increased levels of fibronectin 1 (FN1).16
The clinical outcome of renal cell cancer (RCC) patients var-
ies considerably, especially among individuals presenting without 
metastases. The prognosis for localized disease is good with a 
five-year survival rate of more than 90% upon tumor removal 
via radical or partial nephrectomy.17 However, due to the lack 
of major symptoms, about one-third of patients bears metastatic 
disease at time of diagnosis, and 25–50% of patients treated for 
local disease will develop metastasis.18 The survival of metastatic 
RCC is dramatically low, with a five-year survival rate of less 
than 15%. In this setting, treatment options are often limited by 
radio- and chemotherapy resistance.19
RCCs are largely considered as immunogenic tumors and are 
frequently infiltrated by immune cells.20 However, in contrast to 
breast carcinoma, bladder carcinoma and other cancers (reviewed 
in ref. 1), an elevated number of tumor-infiltrating leukocytes 
(TILs) is associated with poor prognosis in RCC.21 To better 
understand the local mechanisms that preclude the control of 
clinically apparent RCC by the immune system, we correlated 
intratumoral immunological profiles with survival and tumor 
stage (pT) in patients affected by primary clear cell renal cell car-
cinoma (ccRCC), which is the most frequent subtype of RCC. 
Furthermore, we investigated the impact of the tumor microen-
vironment on T-cell phenotype and function.
Results
Correlation between the expression of immune response-related 
transcripts and survival in ccRCC. To better understand the 
local immunosuppressive mechanisms that preclude the immune 
system to control clinically manifest RCC, we correlated intratu-
moral immunological profiles with survival in 54 patients affected 
by primary ccRCC. We retrospectively analyzed the expression 
of 31 immune response-related transcripts (Table S1A) by quan-
titative reverse transcription real-time PCR (qRT-PCR) using a 
collection of formalin-fixed paraffin-embedded (FFPE) tumor 
tissues from ccRCC patients, for which information on tumor 
size and disease course was available. The samples of patients who 
died of tumor-unrelated causes were excluded from the analysis 
(Table S2). Using the Cox proportional hazard model, we found 
no significant correlation between the degree of leukocyte infil-
tration (Ct values of CD45 normalized to those of the 18S rRNA) 
and survival (Fig. 1A).
Subsequently, we quantified the transcripts of immune 
response-related genes upon normalization to the expression level 
of CD45, which allows for the qualitative analysis of the infiltrate 
independent of the degree of infiltration. We correlated each of 
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CD163high TAMs exhibit an M2-phenotype. We further 
characterized TAMs from 12 fresh primary ccRCC tumor sam-
ples by flow cytometry. Tumors from most patients contained a 
iNOS (an M1-associated factor) (Fig. 1C) suggesting that TAMs 
with an M2-like signature negatively influence the survival of 
ccRCC patients.
Figure 1. FOXP3 and CD68 and genes associated to M2 tumor-associated macrophages inversely correlate with survival in clear cell renal cell carci-
noma patients. (A–C) Fifty-four clear cell renal cell carcinoma (ccRcc) formalin-fixed paraffin-embedded (FFpe) tumor samples were subjected to a 
retrospective qRT-pcR analysis for different immune response-related genes. Δct levels of CD45 were calculated by normalization to the endogenous 
control (18S rRNa), Δct levels of all other genes were calculated by normalization to CD45. survival analysis was performed using the cox proportional 
hazard model and, after dichotomizing the data based on the mean-expression level, the log-rank test of the Kaplan-Meier estimator. The results of 
both statistical tests are displayed for selected genes. patients that were still alive at time of analysis are marked with a tick. Kaplan-Meier survival 
curves show the relationship between gene expression and survival for CD45, CD3, FOXP3 and CD68 (A) and iNOS, CD163, FN1 and IRF4 (B). Multivariate 
cox regression analysis revealed that the correlation of target gene expression and survival is independent of tumor grade for CD68: p = 0.02, hazard 
ratio (hR) = 0.704, 95% cI 0.520–0.954; iNOS: p = 0.011, hR = 1.261, 95% cI 1.055–1.506 and CD163 p = 0.015, hR = 0.645, 95% cI 0.453–0.919, as well as 
independent of patient age for CD68: p = 0.04, hR = 0.720, 95% cI 0.524–0.989; iNOS: p = 0.012, hR = 1.299, 95% cI 1.060–1.592 and CD163: p = 0.013, 
hR = 0.636, 95% cI 0.445–0.909. (C) Δct levels of CD163 plotted against Δct values of IL-10-, MR-, FN1- and iNOS-coding transcripts. Results of spearman 
Rho correlation analysis are depicted. each dot represents an individual patient.
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(Fig. S6A). At the mRNA level, a slight increase in the expres-
sion of M2-related genes coding for CD163, c-MYC and IL-10 
was observed, coupled to a strong elevation in FN1 (Fig. S6B). 
Of note, the M1-associated factor iNOS was upregulated in two 
samples, while IL-12 was not expressed in two samples and lost in 
one upon co-culture with tumor cells. Because we only had suf-
ficient material from a limited number of patients, we could not 
investigate this phenomenon in a larger series of samples.
In summary, the CD45+CD3−CD19−CD68+CD11b+CD163high 
T
2
 population, which is found in ccRCCs but not in paired 
peripheral blood samples, shows features of tumor-promoting 
TAMs with an M2-like signature. Our findings indicating 
that the intratumoral levels of CD163 transcripts correlate with 
reduced survival and increased tumor grade lend further support 
to this notion. Furthermore, we demonstrated that malignant 
cells favor the M1 → M2 skewing of TAMs, which is in line with 
the progressive accumulation of T
2
 TAMs within ccRCC lesions.
The ccRCC microenvironment impacts on the pheno-
type and function of T cells. We noticed a correlation between 
high tumor stage and elevated FOXP3 or IL-10 expression lev-
els (Fig. S7), suggesting a progressive accumulation of Tregs and 
IL-10 in the tumor. To investigate the impact of the immunoregu-
latory tumor microenvironment on the phenotype and function 
of T cells we sorted CD45RA−CD4+ and CD45RA−CD8+ T cells 
from fresh ccRCCs (Table S3) and from paired peripheral blood 
samples. We sorted CD45RA− (antigen-experienced) T cells 
because the proportion of antigen-experienced T cells in tumors 
was much higher than in paired blood samples (Fig. 4A) and these 
T cells have a lower threshold for in vitro cytokine production 
upon stimulation than naïve T cells.27 The abundance of tran-
scripts coding for effector cytokines including TNFα, interferon 
γ (IFNγ), IL-2 and for the cytotoxic molecule granzyme B was 
higher in tumor-derived CD4+ and CD8+ T cells than in blood-
derived CD4+ and CD8+ T cells (Fig. 4B and C). Alongside, how-
ever, tumor-derived T cells contained elevated levels of transcripts 
coding for immunoregulatory molecules including programmed 
death 1 (PD-1), T-cell immunoglobulin mucin 3 (TIM-3) and 
IL-10. Furthermore, tumor-derived CD4+ T cells expressed higher 
levels of FOXP3, IL-17 and the T
H
2 cytokines IL-4 and IL-13. 
Only a slight increase in TGFβ was observed in TILs, which 
may be explained by the fact that TGFβ is mainly regulated at 
a post-translational level (Fig. 4B and C). By flow cytometry, we 
confirmed that TIL-derived T cells were in an activated state, as 
demonstrated by the strong expression of the activation marker 
CD69, and confirmed the increased expression of PD-1, TIM-3, 
CTLA-4 and FOXP3 at the protein level (Fig. 5A and B; Fig. S8). 
Altogether, these data suggest that ccRCCs are sites characterized 
by an active immune response, which manifests features reminis-
cent of immune regulation or chronic inflammation.28,29
To confirm the alterations of the cytokine profile in tumor-
derived T cells at the protein level, and to investigate the role 
of the tumor microenvironment on these functional deviations 
toward a more regulated phenotype, we polyclonally stimulated 
CD45RA− antigen-experienced T cells in the presence of the 
whole tumor singe-cell suspension and compared their cytokine 
production profile with that of CD45RA− T cells from the same 
subpopulation of CD45+CD3−CD19−CD68+CD11b+CD163high 
cells (termed T
2
 population hereafter), which was absent in 
matched peripheral blood samples. In the peripheral blood as 
well as in tumors, we found populations that we termed P
1
 and 
T
1
 population, respectively, both of which were characterized 
by a CD45+CD3−CD19−CD68+CD11b+CD163low phenotype 
(Fig. 2A). Both T
1
 and T
2
 TAMs expressed higher levels of MHC 
Class II molecules than P
1
 cells, suggesting that TAMs exist in an 
activated state (Fig. 2B; Fig. S4). Based on the elevated expression 
of CD163 and MR, the T
2
 population classifies as M2 TAMs. 
Furthermore, the T
2
 but neither the T
1
 nor the P
1
 population 
exhibited increased expression of the programmed death ligand 1 
(PD-L1) (Fig. 2B; Fig. S4). To further strengthen the presump-
tion that CD163 associates with M2 TAMs, we analyzed the 
expression levels of different M1- and M2-related genes on sorted 
T
2
 TAMs by qRT-PCR (Table S1). When we compared T
2
 and P
1
 
cells for the expression of M2-associated genes, the former exhib-
ited a strong elevation of FN1- and IL-10-coding transcripts that 
was accompanied by a slight increase in the expression of IRF-4 
and of the transcription factor c-MYC,22 whereas the expression of 
the M1-associated genes IRF5, iNOS and IL-12 was low (Fig. 2C). 
Except for the elevated expression of CD163 and MR, no clear dif-
ferences between the expression of M1- and M2-assocaited genes 
were observed in the T
2
 as compared with the T
1
 population, at 
least at the mRNA level (Fig. S5).
The expression of M2-associated transcripts correlates with 
tumor progression. RCC patients who develop metastasis have a 
poor prognosis, with a five-year survival rate of less than 15%.23 
We observed a similar correlation between reduced survival and 
the incidence of metastasis (Fig. 3A). High levels of FOXP3 or 
CD68 transcripts also correlated with the incidence of metasta-
sis, whereas the expression of CD45 and CD3 did not (Fig. 3B). 
A correlation between tumor infiltration by macrophages and 
metastasis has been documented in various types of cancer.24 In 
this context, a role has been proposed for the paracrine and auto-
crine signaling axis involving colony-stimulating factor 1 (CSF1), 
epidermal growth factor (EGF)25 as well as the actin-binding pro-
tein mammalian enabled (MENA).26 However, in our cohort of 
primary ccRCC patients, we did not observed a significant corre-
lation between the expression levels of CSF1, EGF, their receptors 
and MENA with survival (Fig. S1C).
Conversely, we found a significant correlation between low 
iNOS expression levels and increased tumor stage and a simi-
lar trend for high levels of CD163 transcripts (Fig. 3C). These 
data suggest a progressive accumulation of, or a conversion to, 
CD163high M2 macrophages at the expense of iNOShigh M1 mac-
rophages within ccRCC, which correlates with reduced patient 
survival.
ccRCC cells contribute to the M1 → M2 conversion of 
myeloid cells. To investigate whether freshly isolated ccRCC 
tumor cells can induce tumor-promoting changes in myeloid 
cells, we co-incubated P
1
 cells (sorted from the peripheral blood) 
with autologous CD45− cells (obtained from tumor samples) 
for 48 h at a 1:3 ratio, followed by the analysis of P
1
 cells. Such 
a co-culture induced the upregulation of CD163 and MR in 
blood-derived myeloid cells, as observed at the protein level 
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Figure 2. characterization of tumor-associated myeloid cells in clear cell renal cell carcinoma. (A–C) Fresh primary clear cell renal cell carcinoma 
(ccRcc) and paired peripheral blood samples were collected and processed as described under Materials and Methods. (A) Dot plots display the 
staining of peripheral blood mononuclear cells (pBMcs, left histogram) and processed tumors (right histogram) for cD11b and cD163 after gat-
ing on cD45+cD3−cD19− cells. p1, T1 and T2 designate individual myeloid cell populations. The plots show a representative example of one patient. 
(B) expression of different macrophage-associated molecules after gating on p1, T1 and T2 populations, displayed as the geometric mean of fluores-
cence intensity. each symbol represents an individual patient; means and significant differences (*p < 0.05) are displayed. (C) qRT-pcR analysis of 
Facs-sorted p1 and T2 cell fractions. The genes displayed on the left side of the vertical line are related to M2 TaMs, on the right side to M1 TaMs. Δct 
levels were calculated upon normalization to the endogenous control PPIA. Results are presented as fold change in expression level of T2 relative to p1; 
the geometric mean of each group is depicted. Fold differences in expression within the shaded area are considered as not significant. symbols at the 
0.0001 line on the y-axis represent samples for which the fold change could not be calculated, since the expression was only detected the p1 fraction. 
each symbol in (B) and (C) represents an individual patient.
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was lower, as compared with the same 
T cells in the presence of their natural 
tumor environment (Fig. 6A). The dif-
ference in effector cytokine production 
between sorted and non-sorted cells was 
less pronounced for CD8+ T cells, whereas 
the production of IL-10 was supported by 
the presence of the tumor (Fig. 6B). We 
detected a very low percentage of IL-17-
producing cells, which was comparable 
in sorted and non-sorted cells (Fig. S9). 
We conclude that the tumor microenvi-
ronment induced the skewing toward a 
more regulated phenotype upon T-cell 
receptor (TCR)-dependent (anti-CD3/
CD28-coated beads) as well as TCR-
independent (phorbol 12-myristate 
13-acetate plus ionomycin) stimulation.
M2 TAMs impact on the cyto-
kine profile of CD4+ T cells. TAMs 
have been described to suppress tumor-
specific immunity.30,31 To investi-
gate whether the intratumoral T
2
 
population contributes to the immune 
subversion of tumor-infiltrating anti-
gen-experienced T cells, we stimulated 
sorted, blood-derived CD45RA−CD4+ 
cells with anti-CD3/CD28-coated 
beads in the presence or absence of 
autologous, sorted, tumor-derived T
2
 
(CD45+CD2−CD19−CD11b+CD163high) 
cells (Fig. S10). Because of the limited 
availability of material, we could only 
perform TCR-dependent stimulation for 
CD4+ T cells. Peripheral blood-derived 
CD4+ T cells produced significantly less 
IL-2 and significantly more TGF-β, IL-10 
and IL-4 upon the addition of autologous 
T
2
 TAMs (Fig. 7A). The production of 
the effector cytokines IFNγ und TNFα 
followed the same trend as IL-2; although 
the effect was not statistically significant. 
Furthermore, the co-incubation with T
2
 
TAMs resulted in an upregulation of the 
transcripts coding for PD-1 and TIM-3 
(Fig. 7B). No changes in T-cell func-
tion were observed when T cells were 
co-cultured with the sorted T
1
 fraction 
(CD45+CD2−CD19−CD11b+CD163low) 
(data not shown). There was a trend 
toward a reduced proliferation of T cells in 
the presence of the T
2
 fraction, but results 
were not consistent (data not shown). 
These results indicate that CD45+CD2−CD19−CD11b+CD163high 
cells contribute to functional and phenotypic immune subversion 
of tumor-infiltrating T cells in ccRCC patients.
source that were previously sorted. The production of the effec-
tor cytokines IFNγ and IL-2 by sorted CD4+ T cells was higher, 
whereas the production of the immunoregulatory cytokine IL-10 
Figure 3. positive correlation of FOXP3 and CD68 gene expression with the incidence of metastasis 
and of M2-associated genes with tumor stage. (A) survival in months after diagnosis versus inci-
dence of metastasis. (B) The Δct values of CD45, CD3, FOXP3 and CD68 correlated with the incidence 
of metastasis (0 = patient did not develop metastasis, 1 = patient developed metastasis). (C) The Δct 
values of CD163 and iNOS correlated with tumor stage (pT). each dot represents an individual pa-
tient. Δct levels were calculated as in the legend of Figure 1. Only when correlations are significant, 
the results of the spearman Rho correlation test are displayed. Tumor stage was defined as: 1 = pT1, 
1.25 = pT1a, 1.5 = pT1b, 2 = pT2, 3 = pT3, 3.25 = pT3a, 3.5 = pT3b, 3.75 = pT3c and 4 = pT4.
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M1-associated factor iNOS and prolonged survival as well as 
between an increased expression of M2-associated genes (CD163, 
FN1 and IRF4) and reduced survival. iNOS has previously been 
correlated with increased survival in colorectal cancer patients.45 
Furthermore, a correlation between CD163 and reduced survival 
has been recently observed in different types of cancer, including 
ccRCC.46,47 Subsequent analysis of prospectively collected fresh 
tumor samples showed the presence of two different myeloid frac-
tions in primary ccRCC lesions: CD11b+CD68+CD163high (T
2
) 
and CD11b+CD68+CD163low (T
1
) cells, whereas we only found 
CD11b+CD68+CD163low cells in paired peripheral blood samples 
(P
1
 cells). The T
2
 population expressed high levels of MR, FN1 
and IL-10 and low levels of iNOS, thus uncovering CD163 as 
a marker for TAMs with an M2-like signature in ccRCC.5,44 
T
2 
cells—but neither T
1
 nor P
1
 cells—showed increased expres-
sion of molecules that are involved in immunosuppression, 
including PD-L1 and IL-10. We noticed that differences in the 
CD163 signal between the different fractions were not as pro-
nounced at the mRNA level as they were at the protein level. One 
explanation for this observation may be that CD163 transcripts 
are less stable than the corresponding protein. The high level of 
MHC Class II molecules on the T
2
 fraction clearly discriminates 
them from CD11b+MHC-II−/low MDSC.6,48
TAMs can support tumor progression in multiple ways, e.g., 
by promoting the survival of tumor cells, invasion, metastasis 
and angiogenesis.8 Our analyses showed a correlation between 
CD68 transcripts and the incidence of metastases. We observed 
a correlation between increased CD163 levels and tumor stage, 
while the opposite held true for iNOS. This suggests a progressive 
accumulation of M2 TAMs in ccRCC lesions, which may be due 
to an increased influx of M2 TAMs10 or to the conversion of M1 
to M2 macrophages in situ.9,48,49 Our data support the second sce-
nario, since we observed the induction of M2-associated markers 
on peripheral blood-derived myeloid cells upon co-culture with 
autologous tumor cells. These findings are in line with another 
study showing that the supernatants of ccRCC cell lines induce 
the expression of M2 markers by human macrophages.49
The observations that the levels of the transcripts coding for 
CD163, FOXP3 and IL-10 positively correlate with tumor stage 
suggests that the immune regulation increased during tumor pro-
gression.7,50,51 Along this line, transcripts coding for the effector 
molecules TNFα and perforin positively correlated with survival, 
whereas the opposite was true for those encoding CTLA-4 and 
IL-10. Functional TIL analysis confirmed these observations: 
although TILs showed an antigen-experienced (CD45RO+) and 
activated (CD69+, IFNγ+, TNFα+) phenotype, they simultane-
ously expressed high levels of PD-1, TIM-3, CTLA-4 and IL-10, 
all of which are indicative of ongoing immunoregulation. The 
increased expression of PD-1 and TIM-3 was more pronounced 
in tumor-derived CD8+ T cells than on their CD4+ counterparts, 
whereas CTLA-4 and FOXP3 expression was more prominent in 
tumor-derived CD4+ T cells than in CD8+ T cells. This suggests 
that CD4+ and CD8+ T cells may be subject to different mecha-
nisms of immunoregulation in the tumor. In particular, the sig-
nificant increase of the PD-1+/TIM-3+ population is indicative 
of an exhausted T-cell phenotype52 and implies reduced effector 
Discussion
Growing evidence indicates that the immunoregulatory milieu 
that is associated with most tumors precludes protective antitu-
mor immunity and compromises the efficacy of immunother-
apy.32 To better understand local immunoregulatory processes 
that impact on ccRCC progression, we correlated intratumoral 
immunological profiles with survival in patients affected by pri-
mary ccRCC. In addition, we performed functional experiments 
to dissect the mutual influences of tumor cells, TAMs and T cells.
We retrospectively analyzed the transcripts coding for 31 
immune response-related genes in 54 FFPE primary ccRCC 
samples, and correlated the expression of each of these genes with 
survival. In line with the finding that the subtype function and 
location of leukocytes, rather than the degree of infiltration are 
relevant to disease outcome,1 we did not observe a correlation 
between the extent of leukocyte CD45 mRNA level infiltration 
and survival. Data on the impact of tumor infiltrating leukocytes 
(TILs) on ccRCC outcome are conflicting. Whereas one study 
has shown that an increased frequency of CD8+ T cells corre-
lates with poor prognosis, except when these T cells are prolif-
erating,33 another report shows a correlation between increased 
T
H
1 responses and improved prognosis.34 Furthermore, it has 
recently been shown that an increased abundance of intratumoral 
lymphocytes negatively impacts the overall survival of ccRCC 
patients.21 Among all lymphocyte-associated transcripts, only the 
expression levels of FOXP3, coding for a Treg-specific transcrip-
tion factor35 correlated with decreased survival, which is in line 
with previous findings.36,37 Tregs are a subpopulation of T cells 
that play an important physiological role in suppressing effector 
responses to self-antigens, thereby preventing autoimmunity.38 
Furthermore, Tregs suppress antitumor immunity.7,39 A correla-
tion between increased numbers of intratumoral Tregs or a low 
ratio between effector T cells and Tregs and reduced survival has 
been shown in several cancer types, including ccRCC.39,40
We discovered that increased levels of transcripts coding 
for the macrophage marker CD68 correlate significantly with 
reduced survival in primary ccRCC patients. Although most 
often an increased frequency of TAMs has been correlated with 
unfavorable prognosis in patients affected by breast, prostate, 
bladder or kidney cancer, some studies involving patients bear-
ing melanoma, gastric and colocrectal cancer report opposite 
findings (summarized in ref. 8). A possible explanation for these 
conflicting observations may be the use of the pan-macrophage 
marker CD68, which recognizes all the subsets of this highly 
heterogeneous and plastic cell population41 and notably does not 
differentiate between functionally different M1 and M2 macro-
phages.42,43 Pro-inflammatory M1 macrophages are induced by 
IFNγ and lipopolysaccharide (LPS), whereas alternatively acti-
vated, anti-inflammatory M2 macrophages differentiate in the 
presence of IL-4, IL-13 and IL-10.5 M2 macrophages dampen 
immune and inflammatory responses to prevent tissue damage in 
the case of chronic inflammation.44 Moreover, M2 macrophages 
promote tumor progression, metastasis and immunosuppres-
sion.43 For this reason we expanded our retrospective analysis 
with 12 TAM-associated genes and found a correlation between 
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Figure 4. For figure legend, see page e23562-9.
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of Pathology, University Hospital Zurich. All patients met the fol-
lowing criteria: (1) a new renal tumor diagnosis with histological 
confirmation of a clear cell renal tumor subtype according to the 
2004 WHO classification; (2) no prior treatment for renal can-
cer. The local ethical committee approved this study (KEK ZH, 
STV38-2005). Six patients died of causes not related to cancer 
and were excluded from the analysis. A summary of the patients’ 
characteristics can be found in Table S2.
Fresh ccRCC tumor samples and blood. Twenty renal can-
cer patients were enrolled in the study. The patients underwent 
full or partial nephrectomy as part of their standard treatment at 
the Department of Urology, University Hospital Zurich. Tumor 
samples and peripheral blood were prospectively collected fol-
lowing informed consent in accordance with the Declaration of 
Helsinki. The local ethics committee and Swissmedic approved 
the study (EK-1017). All patients met the criteria described 
above. A summary of the patients’ characteristics can be found 
in Table S3. Peripheral blood mononuclear cells (PBMCs) were 
isolated by Ficoll (Ficoll-PaqueTM PLUS; GE Healthcare) 
density centrifugation. The tumor material was cut into mul-
tiple pieces of 2–4 mm3 and further dissociated with 6 U/mL 
functions of CD8+ T cells within ccRCCs. The tumor environ-
ment itself, or (more specifically) TAMs, contribute to the regu-
lated phenotype of T cells because the effector functions of the 
latter was partially rescued by sorting CD4+ and CD8+ T cells 
out of the tumor. The reverse experiment, that is, the addition of 
sorted CD11b+CD163high cells (T
2
 fraction) from primary ccRCC 
tumor samples to autologous blood-derived CD4+ T cells, con-
firmed the negative impact of TAMs on T-cell effector function.
In conclusion, we found that an intense infiltration of primary 
ccRCC by Tregs and M2 TAMs correlates with reduced survival. 
Furthermore, we showed a progressive accumulation of (and/or 
the local conversion to) M2 macrophages, which is supported by 
tumor cells. M2 TAMs in turn induce the skewing of tumor-
infiltrating T cells toward a more regulated phenotype at the 
expense of protective effector functions.
Materials and Methods
Paraffin embedded patient material. Formalin-fixed, paraffin-
embedded material from 60 patients bearing ccRCC collected 
from 1993 to 2003 was identified in the archives of the Department 
Figure 4 (See previous page). Tumor-derived T cells show an antigen-experienced and regulated phenotype. (A) The percentage of cD45Ra− 
(antigen-experienced) T cells in the peripheral blood and tumors of clear cell renal cell carcinoma (ccRcc) patients was determined by flow cytometry; 
the means of each group and significant differences (*p < 0.05) are displayed. (B and C) Gene expression analysis was performed by qRT-pcR on Facs-
sorted cD45Ra−cD8+ (B) and cD45Ra−cD4+ (C) cells from the peripheral blood and tumors of ccRcc patients. ct values were normalized to the endog-
enous control PPIA. The genes displayed on the left side of the vertical lines are related to immunoregulation, on the right side to effector functions. 
Results are presented as fold change in expression level of tumor-derived relative to peripheral blood-derived T cells; the geometric mean of each 
group is depicted; fold differences in expression within the shaded area are considered as not significant. each symbol represents an individual patient.
Figure 5. Tumor-derived T cells express higher levels of regulatory molecules than T cells derived from paired blood samples. (A and B) Facs analysis 
on tumor- and peripheral blood-derived cells after gating on cD8+cD45Ra− T cells (A) or cD4+cD45Ra− T cells (B). The graphs display the percentage 
of cells positive for a particular marker. a representative staining is shown in Figure S4. each symbol represents an individual patient. The mean of 
each group and significant differences (*p < 0.05; **p < 0.005; ***p < 0.0005) are depicted.
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software (TreeStar). All antibodies used in this study (listed 
in Supplemental Materials and Methods) were purchased from 
BioLegend, BD Biosciences, Beckman Coulter or eBioscience.
FACS sorting of T cells and TAMs from TILs and PBMCs. 
TILs and PBMCs were stained in sorting buffer (SB: PBS supple-
mented with 2% pooled human serum (PAA Laboratories) and 
6 U/mL DNase I TypeIV (Sigma)) and stained with a mixture 
of fluorochrome-conjugated antibodies plus live-dead stain-
ing (LIVE/DEAD® Fixable Violet Dead Cell Stain Kit). After 
staining for 20 min at 4°C cells were washed and resuspended 
in SB. Gates were either placed on CD45+CD8+ T cells or on 
CD45+CD4+ T cells, or—in the case of the simultaneous sort-
ing of T cells and myeloid cells—as shown in the gating strategy 
DNase I Type IV (Sigma) and 1 mg/mL collagenase IV (Sigma) 
in DMEM (Gibco) plus 50 U/mL penicillin and 50 U/mL strep-
tomycin (Gibco) for 1–2 h at 37°C. The digested material was 
afterwards filtered and single-cell suspensions and the PBMCs 
were cryopreserved at -80°C until further analysis.
Flow cytometry for phenotypic analysis. Surface staining 
with fluorochrome-conjugated antibodies was performed in PBS 
together with live/dead staining (LIVE/DEAD® Fixable Violet 
Dead Cell Stain Kit, ViVid, Invitrogen) for 20 min at room 
temperature. Intracellular staining for CD68 and FOXP3 was 
performed according to manufacturer’s instructions (eBiosci-
ence). Staining was measured with a CyAn ADP 9 flow cytom-
eter (Beckman Coulter) and data were analyzed with FlowJo 
Figure 6. The tumor microenvironment impacts on the cytokine profile of T cells. Intracellular staining for cytokines after 6 h ex vivo stimulation with 
anti-cD3/cD28 beads or with phorbol 12-myristate 13-acetate (pMa) + ionomycin in the presence of brefeldin a and monensin. cells were stimulated 
within the tumor single-cell suspension or after sorting of cD45+cD4+ T cells (A) or cD45+cD8+ T cells (B) and analyzed after gating on live cD45+cD4+ 
T cells (A) or live cD45+cD8+ T cells (B). each symbol represents an individual patient. Results of unsorted and sorted T cells from the same patient are 
connected by a thin line. The mean of each group and significant differences (*p < 0.05; **p < 0.005) are depicted.
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T cells (at least 10,000 per well) were either cultured alone or 
with the tumor single-cell suspension or with TAMs (ratio 1:1). 
After the overnight resting period, T cells were stimulated in 
96-well plates in the presence or absence of the tumor digest or 
TAMs with anti-CD3/CD28 Dynabeads (Invitrogen, 111.41D) 
(Ratio T cells:beads = 1:3) or with 50 ng/mL PMA (Sigma) plus 
500 ng/mL ionomycin (Sigma). Stimulation was performed 
for 6 h at 37°C in TC-RPMI supplemented with 10 μg/mL 
brefeldin A (Sigma) and 6 U/mL DNase I Type IV (Sigma). 
Cells were surface-stained with a fluorochrome-conjugated 
(Fig. S10), and the different populations were sorted using a 
FACSAria III cell sorter (BD Biosciences).
Polyclonal stimulation and intracellular cytokine stain-
ing (ICS). After sorting, cells were allowed to rest overnight in 
a 96-well round-bottom plate in TC-RPMI (RPMI) (Gibco), 
supplemented with 2 g/L NaHCO
3
 (Sigma), 2 mM L-glutamine 
(Sigma), 50 U/mL penicillin and 50 U/mL streptomycin (Gibco), 
1× MEM nonessential amino acids (Gibco), 1 mM sodium pyru-
vate (Gibco), 100 μM β-mercaptoethanol (Sigma) and 10% 
pooled human serum plus 6 U/mL DNase I Type IV (Sigma) 
Figure 7. clear cell renal cell carcinoma-derived M2 tumor-associated macrophages skew T cells toward a more regulated phenotype. (A and B) sorted 
peripheral blood-derived cD4+ T cells were cultured for 48 h with or without sorted autologous T2 cells (cD45
+cD2−cD19−cD11b+cD163high) in a ratio of 
1:1. (A) The production of cytokines was assessed via intracellular cytokine stating 6 h after ex vivo stimulation with anti-cD3/cD28 beads in the pres-
ence of brefeldin a and monensin upon gating on live cD45+cD11b−cD4+ cells. Results of the same patient are connected by a thin line. The mean of 
each group and significant differences (* p < 0.05; ** p < 0.005) are depicted. (B) The expression of regulatory molecules was assessed by qRT-pcR. Δct 
levels were calculated by normalizing the ct values of the target genes to the ct values of CD4. Results are presented as fold change in expression level 
of cD4+ T cells co-cultured in the presence of autologous T2 (cD45
+cD2−cD19−cD11b+cD163high) cells relative to cD4+ T cells cultured in their absence. 
Fold differences in expression within the shaded area are considered as not significant. The symbol at the 10,000 line on the y-axis represents a sample 
of which fold change could not be calculated, since expression was only detected after co-culture. each symbol represents an individual patient.
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(Hs03928990_g1), (2) the endogenous control PPIA mRNA 
(Hs99999904_m1) or (3) to the levels of CD4 mRNA (Ct target 
gene-Ct control gene) as stated in the figure legends. Immune 
response-related transcripts other than CD45 were normalized 
to the expression levels of CD45. Because there was no corre-
lation between CD45 transcripts and survival (Fig. 1A), this 
normalization will not obscure potential correlations between 
the expression of other immune response-related genes and sur-
vival. In some cases ΔCt levels were expressed as relative to the 
appropriate control. Therefore, ΔΔCt values were determined 
((ΔCT target–ΔCT control)) and fold change calculated with 
the equation 2−ΔΔCt. Ct values > 38 were interpreted such that the 
gene was not expressed. Changes in the expression levels lower 
than 2-fold (both as upregulation and as downregulation) were 
considered as not significant. This range is illustrated as a shaded 
area in the figures.
Statistical analyses. The relationship between the expression 
of target genes and patient survival was analyzed using a univari-
ate Cox proportional hazard regression model with 95% confi-
dence intervals. The prognostic effect of variables that showed 
a correlation with survival in univariate analysis was tested for 
dependence on age at operation and tumor stage by multivari-
ate Cox regression analysis. Furthermore, data was dichotomized 
based on mean gene expression value of all analyzed samples, log-
rank test performed and Kaplan-Meier curves generated in which 
probability of overall survival was plotted over time. Correlations 
between different parameters were assessed using the Spearman 
Rho correlation test (IBM SPSS statistics software). Wilcoxon 
matched-pairs signed rank test was used to analyze statistical sig-
nificance between groups (GraphPad Prism Software). The crite-
rion for significance was set at p ≤ 0.05.
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antibody cocktail including live-dead staining (LIVE/DEAD® 
Fixable Violet Dead Cell Stain Kit) in PBS for 20 min at room 
temperature in the dark. Subsequently, cells were fixed in 4% 
formalin (Kantonsapotheke Zürich) and permeabilized with 
permeabilization buffer (PB: PBS supplemented with 2% FCS, 
20 mM EDTA, 0.05% NaN
3
 and 0.1% saponin). For intracel-
lular staining, cells were incubated with a mix of fluorescent-
conjugated antibodies in PB for 20 min at room temperature 
in the dark. Cells were washed once with PB and resuspended 
in PBS containing 1% formalin before analysis by flow cytom-
etry, as described above. The antibodies employed in this study 
are listed in Supplemental Materials and Methods. When the 
stimulation of T cells was performed in presence or absence of 
the tumor microenvironment, cytokine production was mea-
sured upon gating on ViViD−CD45+CD14−CD16−CD19−CD8+ 
or ViViD−CD45+CD14−CD16−CD19−CD4+ T cells, and—
in presence or absence of TAMs—upon gating on ViViD−
CD45+CD11b−CD4+ T cells.
RNA isolation. After FACS sorting or after co-culture 
experiments, a fraction of the cells (at least 500 cells) was resus-
pended in TRI Reagent (Ambion) and frozen at -80°C until 
RNA isolation. RNA was isolated using the MagMAXTM-96 for 
Microarrays Total RNA isolation kit (AM1839 Ambion) by the 
No-Spin procedure, according to the manufacturer’s instruc-
tions. RNA isolation from FFPE material was performed using 
Trizol, as described in Supplemental Materials and Methods.
Quantitative reverse transcription real-time PCR (qRT-
PCR). The concentration and purity of RNA was evaluated 
using the NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies). Five-hundred ng RNA were reverse transcribed 
using the high-capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Obtained cDNAs were stored at -20°C until qRT-
PCR analysis. Because of limited material, cDNA of sorted cells 
and paraffin punches was pre-amplified. Pre-amplification was 
performed for 14 cycles according to manufacturer’s instructions 
(TaqMan® PreAmp Master Mix Kit, Applied Biosystems). We 
tested the correlation of expression analyzed on original cDNA 
with that analyzed on pre-amplified cDNA for selected highly 
(CD45, CD68, CD163, TNFα, MHC-II) and lowly (iNOS, 
FOXP3, IL-10, IDO) expressed genes, and found an excellent 
correlation for all, confirming uniform pre-amplification for all 
samples (CD68 and CD163 are shown in Fig. S3). qRT-PCR 
was done on a Rotor-Gene Q real-time PCR cycler (Qiagen) 
using commercially available pre-developed TaqMan reagents 
with optimized primer and probe concentrations (TaqMan® gene 
expression assays, Applied Biosystems) (Table S1).
After an initial hold for 2 min at 50°C and 10 min at 95°C, 
probes were cycled 45 times at 95°C for 15 sec and at 60°C for 60 
sec. All PCR reactions were performed in triplicates. Threshold 
cycle (Ct) values were determined with the Rotor-Gene Q Series 
software 1.7. ΔCt values were calculated by normalizing the 
target mRNA levels to (1) the endogenous control 18S rRNA 
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